Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights.
Merc Cetınkaya A, Tatlı AM, Goktas Aydın S, Kılıckap S, Bılıcı A, Bırıcık FS, Kostek O, Kayıkcıoglu E, Paydas S, Artac M, Teker F, Cıl T, Kaplan MA, Hacıbekıroglu İ, Geredelı C, Bayram E, Altıntas YE, Celebı AS, Kocak MZ, Arak H, Arslan Benlı B, Arvas H, Dınc Sonusen S, Sezgın Goksu S. Merc Cetınkaya A, et al. Among authors: tatli am. Am J Cancer Res. 2026 Jan 15;16(1):282-290. doi: 10.62347/TXSZ9359. eCollection 2026. Am J Cancer Res. 2026. PMID: 41657803 Free PMC article.
The Impact of Concurrent Proton Pump Inhibitors on Nivolumab Response in Metastatic Non-Small Cell Lung Cancer: A Multicenter Real-Life Study.
Hendem E, Koçak MZ, Çetinkaya AM, Dinç G, Çağlayan M, Uğraklı M, Çağlayan D, Araz M, Eryılmaz MK, Sakin A, Eren OÖ, Tatlı AM, Geredeli Ç, Artaç M. Hendem E, et al. Among authors: tatli am. Medicina (Kaunas). 2026 Jan 20;62(1):214. doi: 10.3390/medicina62010214. Medicina (Kaunas). 2026. PMID: 41597500 Free PMC article.
Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS study.
Ozveren A, Cil T, Bicakli DH, Gultekin G, Dogan D, Zengin C, Bilici A, Sabir S, Ercelep O, Eksi F, Selcukbiricik F, Yilmaz M, Ergene G, Tatli AM, Aksoy FK, Uysal O, Dizdar O, Yildirim HC, Ozmen N, Ozturk S, Sanli UA, Karabulut B. Ozveren A, et al. Among authors: tatli am. Nutrition. 2026 Mar;143:113029. doi: 10.1016/j.nut.2025.113029. Epub 2025 Nov 17. Nutrition. 2026. PMID: 41455457
Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study.
Uysal M, Saglam S, Beypınar İ, Saglam EK, Mammadov E, Ocak B, Aybi O, Arıkan R, Ergen SA, Gursoy P, Sakin A, Kaya V, Ozden E, Eren T, Demiray AG, Oyman A, Tatli AM, Turk HM, Gulmez A, Demir A, Alan Ö, Sakalar T, Sen E, Ucar G, Kilickap S, Bilici A, Oksuz DC, Karabulut B. Uysal M, et al. Among authors: tatli am. Cancer Invest. 2026 Feb;44(2):127-135. doi: 10.1080/07357907.2025.2595536. Epub 2025 Dec 5. Cancer Invest. 2026. PMID: 41347635
Correction: Kalkan et al. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study. Medicina 2025, 61, 638.
Kalkan Z, Ebinc S, Arcagok M, Bilici A, Yildiz O, Kilickap S, Guven DC, Tatli AM, Sumbul AT, Mandel NM, Ozturk A, Bardakci M, Karakaya S, Kaplan MA. Kalkan Z, et al. Among authors: tatli am. Medicina (Kaunas). 2025 Nov 7;61(11):1997. doi: 10.3390/medicina61111997. Medicina (Kaunas). 2025. PMID: 41303909 Free PMC article.
Failure patterns and the influence of the TNM staging systems on prognosis in limited disease small cell lung Cancer (SCLC): the Turkish Oncology Group (TOG) study.
Ergen ŞA, Dinçbaş FÖ, Metcalfe E, Gül ŞK, Akyürek S, Yavaş G, Özdemir BŞ, Yücel B, Altınok A, Atalar B, Altınok P, Yakar M, Tepetam H, Birgi SD, Yavaş Ç, Korcum AF, Tatlı AM, Yumuk F. Ergen ŞA, et al. Among authors: tatli am. Clin Transl Oncol. 2025 Oct 24. doi: 10.1007/s12094-025-04092-9. Online ahead of print. Clin Transl Oncol. 2025. PMID: 41134441
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study.
Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ; CAPItello-281 Study Group. Fizazi K, et al. Ann Oncol. 2026 Jan;37(1):53-68. doi: 10.1016/j.annonc.2025.10.004. Epub 2025 Oct 19. Ann Oncol. 2026. PMID: 41120017 Free article. Clinical Trial.
72 results